Myrexis, Inc.

Myriad Pharmaceuticals, Inc.

Benjamin Markovitz

Mark B Anderson

Ashok Bajji

Richard Trovato

Daniel Wettstein

Mark Shenderovich

Se-Ho Kim

Rajendra Tangallapally

John A Vanecko

The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L, L, are as defined herein.

Purine-core inhibitors of HSP90 and their use in treating cancer

The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

Therapeutic compounds and their use in cancer

Growing community of inventors

Columbus, OH, United States of America

Benjamin Markovitz